NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

Core Insights - NextCure, Inc. reports promising preclinical data for LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC), and plans to file an Investigational New Drug (IND) application by year-end [1][2] - The company also presents biomarker data from the NC410 combination study with pembrolizumab for colorectal cancer patients [1] Preclinical Data on LNCB74 - LNCB74 is designed with a drug-to-antibody ratio of 4 (DAR4) and utilizes LigaChem Biosciences' ConjuAllTM technology for improved stability and selective payload release in tumor cells [2] - The ADC shows specific binding to B7-H4 expressing tumor cells, mediates potent cytotoxicity with sub-nanomolar to low nanomolar EC50 values, and demonstrates strong anti-tumor activity in various tumor models [3] - A single dose of 3 mg/kg resulted in durable tumor regression, indicating comparable or superior activity to existing B7-H4 targeting ADCs [3] - LNCB74 has favorable pharmacokinetics and stability in rodents and was well tolerated in cynomolgus monkeys at doses up to 10 mg/kg [3] Phase 1b Study of NC410 - The Phase 1b study evaluates NC410, a LAIR-2 fusion protein, in combination with pembrolizumab for ovarian cancer and ICI-naïve MSS/MSI-L colorectal cancer [4] - The combination shows clinical activity against MSS/MSI-L CRC, with subjects achieving partial responses or stable disease demonstrating meaningful durability [4] - Among 43 evaluable ICI-naïve MSS/MSI-L CRC patients, there were 3 partial responses, with disease control rates of 86% and 47% for 200 mg and 100 mg NC410 doses, respectively [5] Biomarker Data for NC410 - Biomarker data supports the proposed mechanism of action for NC410, indicating tumor microenvironment remodeling and enhanced immune infiltration [6] - Treatment with NC410 was well tolerated [6] Presentation Details - NextCure will present findings on LNCB74 and NC410 at the Society for Immunotherapy of Cancer (SITC) annual meeting on November 8 and 9, 2024 [7] Company Overview - NextCure is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies that target patients unresponsive to current treatments, utilizing differentiated mechanisms including ADCs and proteins [8]